Can the response to 23-valent pneumococcal vaccine in splenectomised patients be predicted?

Anna Llupià, Anna Vilella, Laura Costas, Consolación Díez, Ferran Torres, Jordi Yagüe, Montserrat Massó, Ana Muñoz, Josep Mensa

Research output: Contribution to journalArticleResearchpeer-review

8 Citations (Scopus)


The 23-valent pneumococcal vaccine has unequal effectiveness in splenectomised patients. We performed a longitudinal study (2005-2008) whose main objective was to characterize the profile of non-responders among splenectomised patients treated at our institution and identify potential predictive indicators of the response to the vaccine. The immune response was evaluated in 96 subjects. The proportion of responders was 70% (95% CI: 60-78%). Immunosuppression (OR = 3.19, 95% CI 1.04-9.73) and the reason for splenectomy (hematologic neoplasia versus non-malignant hematologic diseases, OR = 7.37, 95% CI 1.71-31.7) were independent predictors of non-response to vaccination. However, the positive predictive value of the model and the likelihood ratio for a positive result were low (PPV = 76.6%, 95% CI 66.2-84.4%, LR(+) = 1.41, 95% CI 1.08-1.86). We recommend determining the response to pneumococcal vaccine in these patients when possible. © 2011 Elsevier Ltd.
Original languageEnglish
Pages (from-to)2382-2386
Issue number13
Publication statusPublished - 16 Mar 2012


  • Response to vaccination
  • Splenectomy
  • Streptococcus pneumoniae


Dive into the research topics of 'Can the response to 23-valent pneumococcal vaccine in splenectomised patients be predicted?'. Together they form a unique fingerprint.

Cite this